|
1. |
Presentation, Diagnosis, and Management of Enterovirus Infections in Neonates |
|
Pediatric Drugs,
Volume 6,
Issue 1,
2004,
Page 1-10
Mark J Abzug,
Preview
|
PDF (222KB)
|
|
摘要:
The nonpoliovirus enteroviruses commonly infect newborns, with consequences ranging from asymptomatic infection and benign illness, to severe, life-threatening disease. Frequently occurring symptoms include fever, irritability, lethargy, anorexia, and rash. Although most illnesses are mild, severe disease develops in a subset of newborns infected in the first 2 weeks of life. Severe disease may consist of sepsis, meningoencephalitis, myocarditis, pneumonia, hepatitis, and/or coagulopathy. Substantial mortality rates have been reported, and long-term sequelae may occur among survivors. Risk factors and clinical features associated with severe disease include absence of neutralizing antibody to the infecting serotype, maternal illness prior to or at delivery, prematurity, illness onset within the first few days of life, multiorgan disease, severe hepatitis, positive serum viral culture, and specific infecting serotype (e.g. group B coxsackieviruses and echovirus 11).Whereas the mainstay of diagnosis has traditionally been viral isolation in tissue culture, the polymerase chain reaction has been demonstrated to be more sensitive than culture, highly specific, and rapid. Immunoglobulin has been used as a therapeutic agent for neonates with enterovirus disease; however, clinical efficacy has not been proven.Specific antiviral therapy for enteroviruses is in development. Pleconaril is an investigational agent that inhibits viral attachment to host cell receptors and uncoating of viral nucleic acid. It has broad and potent anti-enterovirus activity, excellent oral bioavailability, and is well tolerated. Some clinical trials have demonstrated benefit in children and adults with enterovirus meningitis, and in adults with upper respiratory tract infections caused by picornaviruses (rhinoviruses or enteroviruses). Data summarizing compassionate use for severe enterovirus diseases (including neonatal sepsis) also suggest possible benefit. Limited pharmacokinetic data are available in infants and neonates. A multicenter, placebo-controlled, randomized trial of pleconaril in neonates with severe hepatitis, coagulopathy, and/or myocarditis is currently being conducted.
ISSN:1174-5878
出版商:ADIS
年代:2004
数据来源: ADIS
|
2. |
Emergency Department Management of Pain and Anxiety Related to Orthopedic Fracture CareA Guide to Analgesic Techniques and Procedural Sedation in Children |
|
Pediatric Drugs,
Volume 6,
Issue 1,
2004,
Page 11-31
Robert M Kennedy,
Jan D Luhmann,
Scott J Luhmann,
Preview
|
PDF (320KB)
|
|
摘要:
Orthopedic fractures and joint dislocations are among the most painful pediatric emergencies. Safe and effective management of fracture-related pain and anxiety in the emergency department reduces patient distress during initial evaluation and often allows definitive management of the fracture. No consensus exists on which pharmacologic regimens for procedural sedation/analgesia are safest and most effective. For some children, control of fracture pain is the primary goal, whereas for others, relief from anxiety is an additionally important objective. Furthermore, strategies for the management of fracture pain may vary by fracture location and patient characteristics; thus, no single regimen is likely to provide the best means of analgesia and anxiolysis for all patients.Effective analgesia can be provided by local or regional anesthesia, such as hematoma, Bier, or nerve blocks. Alternatively, induction of deep sedation with analgesic agents such as ketamine or fentanyl, often combined with sedative-anxiolytic agents such as midazolam, may be used to manage distress associated with fracture reduction. A combination of local anesthesia with moderate sedation, for example nitrous oxide, is another attractive option.
ISSN:1174-5878
出版商:ADIS
年代:2004
数据来源: ADIS
|
3. |
Weight Gain Associated with Atypical Antipsychotic Use in Children and AdolescentsPrevalence, Clinical Relevance, and Management |
|
Pediatric Drugs,
Volume 6,
Issue 1,
2004,
Page 33-44
Kimberly A Stigler,
Marc N Potenza,
David J Posey,
Christopher J McDougle,
Preview
|
PDF (219KB)
|
|
摘要:
Atypical antipsychotics are increasingly prescribed to children and adolescents with neuropsychiatric disorders. Although their profile of potent antagonism at specific serotonin and dopamine receptors offers certain advantages compared with typical antipsychotics, their use has been associated with various adverse effects, including significant weight gain. This adverse effect is of particular concern in children and adolescents, secondary to the immediate and long-term health risks associated with weight gain, including obesity, diabetes mellitus, and hyperlipidemia. Indeed, from 1963 to 1991, the prevalence of obesity has approximately doubled in youth. Prior to selecting an atypical antipsychotic, a detailed review of the predictors of weight gain is necessary for every child and adolescent. Published data suggest that clozapine and olanzapine are associated with considerable weight gain, whereas risperidone and quetiapine have a moderate risk. Alternatively, ziprasidone and aripiprazole may exhibit a low risk for this adverse effect. Whereas behavioral and pharmacologic measures are available to manage weight gain associated with atypical antipsychotics, research is needed to establish more effective and safe interventions for this adverse effect in children and adolescents.
ISSN:1174-5878
出版商:ADIS
年代:2004
数据来源: ADIS
|
4. |
Drug Dosing During Intermittent Hemodialysis and Continuous Renal Replacement TherapySpecial Considerations in Pediatric Patients |
|
Pediatric Drugs,
Volume 6,
Issue 1,
2004,
Page 45-65
Michael A Veltri,
Alicia M Neu,
Barbara A Fivush,
Rulan S Parekh,
Susan L Furth,
Preview
|
PDF (323KB)
|
|
摘要:
Chronic renal failure is, fortunately, an unusual occurrence in children; however, many children with various underlying illnesses develop acute renal failure, and transiently require renal replacement therapy – peritoneal dialysis, intermittent hemodialysis (IHD), or continuous renal replacement therapy (CRRT). As children with acute and chronic renal failure often have multiple comorbid conditions requiring drug therapy, generalists, intensivists, nephrologists, and pharmacists need to be aware of the issues surrounding the management of drug therapy in pediatric patients undergoing renal replacement therapy. This article summarizes the pharmacokinetics and dosing of many drugs commonly prescribed for pediatric patients, and focuses on the management of drug therapy in pediatric patients undergoing IHD and CRRT in the intensive care unit setting. Peritoneal dialysis is not considered in this review. Finally, a summary table with recommended initial dosages for drugs commonly encountered in pediatric patients requiring IHD or CRRT is presented.
ISSN:1174-5878
出版商:ADIS
年代:2004
数据来源: ADIS
|
5. |
Giving Medicines to ChildrenUnderstanding the Parents’ Views |
|
Pediatric Drugs,
Volume 6,
Issue 1,
2004,
Page 67-69
Dimah Sweis,
Ian CK Wong,
Preview
|
PDF (151KB)
|
|
ISSN:1174-5878
出版商:ADIS
年代:2004
数据来源: ADIS
|
|